Insider Buying: Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Acquires $2,454,344.00 in Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd acquired 322,940 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was bought at an average price of $7.60 per share, with a total value of $2,454,344.00. Following the completion of the acquisition, the insider directly owned 5,200,767 shares in the company, valued at approximately $39,525,829.20. This represents a 6.62% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Wednesday, September 30th, L1 Capital Pty Ltd bought 74,286 shares of Anteris Technologies Global stock. The shares were bought at an average cost of $7.72 per share, for a total transaction of $573,487.92.
• On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.83, for a total transaction of $68,874.00.
• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total transaction of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.10, for a total transaction of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total value of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total value of $120,001.63.
• On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $3,853,113.30.
• On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.15, for a total value of $396,994.65.
• On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.04, for a total value of $1,250,260.20.

Anteris Technologies Global Stock Up 1.3%

Shares of AVR stock opened at $7.71 on Friday. The stock has a market cap of $751.40 million, a price-to-earnings ratio of -3.95 and a beta of 1.87. The business’s fifty day moving average is $8.50 and its 200 day moving average is $7.98. Anteris Technologies Global Corp. has a twelve month low of $3.30 and a twelve month high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The firm had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same period in the prior year, the business posted ($0.58) EPS. Equities research analysts expect that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Anteris Technologies Global

Several institutional investors have recently bought and sold shares of the company. Cetera Investment Advisers grew its holdings in shares of Anteris Technologies Global by 64.7% during the first quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock valued at $92,000 after buying an additional 6,500 shares during the last quarter. Bank of America Corp DE raised its stake in shares of Anteris Technologies Global by 12.6% in the first quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock worth $382,000 after purchasing an additional 7,688 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Anteris Technologies Global during the second quarter valued at $78,000. Bartlett & CO. Wealth Management LLC boosted its position in shares of Anteris Technologies Global by 174.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock valued at $79,000 after buying an additional 8,200 shares during the last quarter. Finally, Abel Hall LLC purchased a new stake in shares of Anteris Technologies Global during the first quarter valued at $63,000.

Analysts Set New Price Targets

AVR has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 target price on shares of Anteris Technologies Global in a report on Friday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.